InterventionsHuman trial

First-in-Human Study Demonstrates GIP Receptor (GIPR) Antagonist AT7687 as Well-Tolerated and Suitable for Once-Weekly Subcutaneous Injection for Treatment in People Living with Obesity

ADA Scientific Sessions 2026 Abstract

The paper

Ayna Baladi Nejad, John Boland, Alan H. Hand,

Kim M. Knudsen, Lærke S. Gasbjerg, Alexander H. Sparre-Ulrich,

Richard Nkulikiyinka

Copenhagen N

ADA Scientific Sessions 2026 Abstract · 7 Jun 2026

Presented at ADA Scientific Sessions 2026 · Oral 1228-OR

doi.org/10.2337/db26-1228-or

A triple-target drug cut body weight by up to 19.7% in a trial
Cell Metabolism · 8 Oct 2026
Survodutide reduces weight in adults with diabetes and obesity
The New England Journal of Medicine · 4 Oct 2026
Retatrutide reduces bodyweight in obesity and type 2 diabetes
Lancet · 4 Oct 2026
Retatrutide reduces weight and pain in adults with obesity
The New England Journal of Medicine · 4 Oct 2026